Ovalbumin locus BACs for expression of biotherapeutics

Information

  • Research Project
  • 6645148
  • ApplicationId
    6645148
  • Core Project Number
    R43GM068200
  • Full Project Number
    1R43GM068200-01
  • Serial Number
    68200
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/1/2003 - 21 years ago
  • Project End Date
    11/1/2003 - 21 years ago
  • Program Officer Name
    SWAIN, AMY L
  • Budget Start Date
    5/1/2003 - 21 years ago
  • Budget End Date
    11/1/2003 - 21 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    -

Ovalbumin locus BACs for expression of biotherapeutics

[unreadable] DESCRIPTION (provided by applicant): With a daily production capacity of two grams of protein per egg, the chicken ovalbumin gene locus has the potential to synthesize large amounts of biopharmaceutical proteins into the eggs of transgenic hens. This phase I SBIR project will test the feasibility of using large expression constructs, based on the complete 200 kilobase chicken ovalbumin gene locus, to drive efficient expression of biopharmaceutical proteins including humanized monoclonal antibodies. The longer-term objectives of the program are to use these constructs in the creation of transgenic hens, in phase II that will produce biopharmaceutical proteins at mg/ml concentration in egg white. In this phase I proposal, we plan to create a complete 200 kilobase ovalbumin gene from two overlapping bacterial artificial chromosomes (BAC) by utilizing recA-assisted restriction endonuclease (RARE) cleavage techniques. Using similar techniques, we will then insert reporter and biopharmaceutical genes into various locations within the transcribed region of the ovalbumin gene. Finally, we will assay protein expression from these constructs using in vitro and in vivo assays. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    81461
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:81461\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SYNAGEVA BIOPHARMA CORPORATION
  • Organization Department
  • Organization DUNS
    967296187
  • Organization City
    Waltham
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02451
  • Organization District
    UNITED STATES